Jane Street Group LLC Takes $30,000 Position in MediciNova, Inc. (NASDAQ:MNOV)

Jane Street Group LLC bought a new position in MediciNova, Inc. (NASDAQ:MNOVFree Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 14,138 shares of the biopharmaceutical company’s stock, valued at approximately $30,000.

MediciNova Price Performance

Shares of MNOV opened at $1.87 on Friday. The business’s 50 day simple moving average is $2.06 and its 200-day simple moving average is $1.74. The company has a market capitalization of $91.72 million, a P/E ratio of -8.90 and a beta of 0.84. MediciNova, Inc. has a one year low of $1.12 and a one year high of $2.55.

Analyst Ratings Changes

A number of research firms recently weighed in on MNOV. D. Boral Capital started coverage on shares of MediciNova in a research note on Monday, December 2nd. They issued a “buy” rating and a $9.00 target price on the stock. StockNews.com assumed coverage on shares of MediciNova in a report on Friday, January 10th. They issued a “hold” rating on the stock.

Get Our Latest Report on MNOV

MediciNova Profile

(Free Report)

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.

Further Reading

Want to see what other hedge funds are holding MNOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MediciNova, Inc. (NASDAQ:MNOVFree Report).

Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.